Skip to menu Skip to content Skip to footer

2019

Conference Publication

Alemtuzumab improves clinical and MRI outcomes, including slowing of brain volume loss, in RRMS patients over 8 years: CARE-MS I follow-up (TOPAZ Study)

Comi, G., Arnold, D. L., Boyko, A. N., Hartung, H. -P., Havrdova, E. K., Inshasi, J. S., McCombe, P., Nakamura, K., Oreja-Guevara, C., Pelletier, D., Pozzilli, C., Selmaj, K. W., Scott, T. F., Chung, L., Daizadeh, N., Afsar, S. and Van Wijmeersch, B. (2019). Alemtuzumab improves clinical and MRI outcomes, including slowing of brain volume loss, in RRMS patients over 8 years: CARE-MS I follow-up (TOPAZ Study). 5th Congress of the European-Academy-of-Neurology (EAN), Oslo Norway, Jun 29-Jul 02, 2019. HOBOKEN: WILEY.

Alemtuzumab improves clinical and MRI outcomes, including slowing of brain volume loss, in RRMS patients over 8 years: CARE-MS I follow-up (TOPAZ Study)

2019

Journal Article

Loss of appetite is associated with a loss of weight and fat mass in patients with amyotrophic lateral sclerosis

Ngo, Shyuan T., Van Eijk, Ruben P. A., Chachay, V. , Van Den Berg, Leonard H., Mccombe, Pamela A., Henderson, Robert D. and Steyn, Frederik J. (2019). Loss of appetite is associated with a loss of weight and fat mass in patients with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 20 (7-8), 1-9. doi: 10.1080/21678421.2019.1621346

Loss of appetite is associated with a loss of weight and fat mass in patients with amyotrophic lateral sclerosis

2019

Journal Article

Gut microbiota in ALS: possible role in pathogenesis?

McCombe, Pamela A., Henderson, Robert D., Lee, Aven, Lee, John D., Woodruff, Trent M., Restuadi, Restuadi, McRae, Allan, Wray, Naomi R., Ngo, Shyuan and Steyn, Frederik J. (2019). Gut microbiota in ALS: possible role in pathogenesis?. Expert Review of Neurotherapeutics, 19 (9), 1-21. doi: 10.1080/14737175.2019.1623026

Gut microbiota in ALS: possible role in pathogenesis?

2019

Journal Article

Women who contributed to past research in multiple sclerosis

McCombe, Pamela A. (2019). Women who contributed to past research in multiple sclerosis. Multiple Sclerosis Journal, 25 (11), 1352458519846101-1443. doi: 10.1177/1352458519846101

Women who contributed to past research in multiple sclerosis

2019

Conference Publication

Investigating the Effect of Teriflunomide on Brain Volume Loss in the Phase 3 TOPIC Study

Sprenger, Till, Lebrun-Frenay, Christine, Vermersch, Patrick, Park, Min Su, Chinchilla, Dennis, McCombe, Pamela, Lincoln, John, Kappos, Ludwig, Bergsland, Niels, Dwyer, Michael, Cavalier, Steven, Roesch, Nora, Somera-Molina, Kathleen, Poole, Elizabeth and Zivadinov, Robert (2019). Investigating the Effect of Teriflunomide on Brain Volume Loss in the Phase 3 TOPIC Study. 71st Annual Meeting of the American-Academy-of-Neurology (AAN), Philadelphia Pa, May 04-10, 2019. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.

Investigating the Effect of Teriflunomide on Brain Volume Loss in the Phase 3 TOPIC Study

2019

Conference Publication

Improved Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in Alemtuzumab-Treated RRMS Patients: 8-Year Follow-up of CARE-MS I (TOPAZ Study)

Pelletier, Daniel, Arnold, Douglas L., Boyko, Alexey N., Comi, Giancarlo, Hartung, Hans-Peter, Havrdova, Eva Kubala, Inshasi, Jihad Said, McCombe, Pamela, Nakamura, Kunio, Oreja-Guevara, Celia, Pozzilli, Carlo, Selmaj, Krzysztof W., Scott, Thomas F., Chung, Luke, Daizadeh, Nadia, Afsar, Salman and Van Wijmeersch, Bart (2019). Improved Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in Alemtuzumab-Treated RRMS Patients: 8-Year Follow-up of CARE-MS I (TOPAZ Study). 71st Annual Meeting of the American-Academy-of-Neurology (AAN), Philadelphia Pa, May 04-10, 2019. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.

Improved Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in Alemtuzumab-Treated RRMS Patients: 8-Year Follow-up of CARE-MS I (TOPAZ Study)

2019

Conference Publication

Improved Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in Alemtuzumab-Treated RRMS Patients: 8-Year Follow-up of CARE-MS I (TOPAZ Study)

Pelletier, Daniel, Arnold, Douglas L., Boyko, Alexey N., Comi, Giancarlo, Hartung, Hans-Peter, Havrdova, Eva Kubala, Inshasi, Jihad Said, McCombe, Pamela, Nakamura, Kunio, Oreja-Guevara, Celia, Pozzilli, Carlo, Selmaj, Krzysztof W., Scott, Thomas F., Chung, Luke, Daizadeh, Nadia, Afsar, Salman and Van Wijmeersch, Bart (2019). Improved Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in Alemtuzumab-Treated RRMS Patients: 8-Year Follow-up of CARE-MS I (TOPAZ Study). AAN 71st Annual Meeting, Philadelphia, PA United States, 4-10 May 2019. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1212/wnl.92.15_supplement.p3.2-037

Improved Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in Alemtuzumab-Treated RRMS Patients: 8-Year Follow-up of CARE-MS I (TOPAZ Study)

2019

Conference Publication

Clinical determinants and therapeutic modifiers of relapse and disability outcomes in neuromyelitis optica spectrum disorder

Kunchok, Amy, Malpas, Charles, Nytrova, Petra, Havrdova, Eva, Alroughani, Raed, Terzi, Murat, Yamout, Bassem, Hor, Jyh Yung, Karabudak, Rana, Boz, Cavit, Ozakbas, Serkan, Olascoaga Urtaza, Francisco Javier, Simo, Magdolna, Granella, Franco, Patti, Francesco, McCombe, Pamela, Csepany, Tunde, Singhal, Bhim, Bergamaschi, Roberto, Fragoso, Yara, Al-Harbi, Talal, Turkoglu, Recai, Lechner-Scott, Jeannette, Laureys, Guy, Oreja-Guevara, Celia, Pucci, Eugenio, Sola, Patrizia, Ferraro, Diana, Altintas, Ayse ... Kalincik, Tomas (2019). Clinical determinants and therapeutic modifiers of relapse and disability outcomes in neuromyelitis optica spectrum disorder. 71st Annual Meeting of the American-Academy-of-Neurology (AAN), Philadelphia, PA, United States, 4-10 May 2019. Philadelphia, PA, United States: Wolters Kluwer Health.

Clinical determinants and therapeutic modifiers of relapse and disability outcomes in neuromyelitis optica spectrum disorder

2019

Journal Article

Cumulative influence of parity-related genomic changes in multiple sclerosis

Mehta, Divya, Wani, Shivangi, Wallace, Leanne, Henders, Anjali K., Wray, Naomi R. and McCombe, Pamela A. (2019). Cumulative influence of parity-related genomic changes in multiple sclerosis. Journal of Neuroimmunology, 328, 38-49. doi: 10.1016/j.jneuroim.2018.12.004

Cumulative influence of parity-related genomic changes in multiple sclerosis

2019

Journal Article

Tract integrity in amyotrophic lateral sclerosis: 6–month evaluation using MR diffusion tensor imaging

Alruwaili, Ashwag R., Pannek, Kerstin, Henderson, Robert D., Gray, Marcus, Kurniawan, Nyoman D. and McCombe, Pamela A. (2019). Tract integrity in amyotrophic lateral sclerosis: 6–month evaluation using MR diffusion tensor imaging. BMC Medical Imaging, 19 (1) 19, 19. doi: 10.1186/s12880-019-0319-3

Tract integrity in amyotrophic lateral sclerosis: 6–month evaluation using MR diffusion tensor imaging

2019

Journal Article

Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: a contemporary cohort study

Nguyen, Ai-Lan, Havrdova, Eva Kubala, Horakova, Dana, Izquierdo, Guillermo, Kalincik, Tomas, van der Walt, Anneke, Terzi, Murat, Alroughani, Raed, Duquette, Pierre, Girard, Marc, Prat, Alexandre, Boz, Cavit, Sola, Patrizia, Ferraro, Diana, Lugaresi, Alessandra, Lechner-Scott, Jeannette, Barnett, Michael, Grand'Maison, Francois, Grammond, Pierre, Ramo-Tello, Cristina, Turkoglu, Recai, McCombe, Pamela, Pucci, Eugenio, Trojano, Maria, Granella, Franco, Spitaleri, Daniele, Van Pesch, Vincent, Soysal, Aysun, Oreja-Guevara, Celia ... Jokubaitis, Vilija (2019). Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: a contemporary cohort study. Multiple Sclerosis and Related Disorders, 28, 235-243. doi: 10.1016/j.msard.2019.01.003

Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: a contemporary cohort study

2019

Journal Article

Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis

Brown, J. William L., Coles, Alasdair, Horakova, Dana, Havrdova, Eva, Izquierdo, Guillermo, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Trojano, Maria, Lugaresi, Alessandra, Bergamaschi, Roberto, Grammond, Pierre, Alroughani, Raed, Hupperts, Raymond, McCombe, Pamela, Van Pesch, Vincent, Sola, Patrizia, Ferraro, Diana, Grand'Maison, Francois, Terzi, Murat, Lechner-Scott, Jeannette, Flechter, Schlomo, Slee, Mark, Shaygannejad, Vahid, Pucci, Eugenio, Granella, Franco, Jokubaitis, Vilija, Willis, Mark, Rice, Claire ... Robertson, Neil (2019). Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA - Journal of the American Medical Association, 321 (2), 175-187. doi: 10.1001/jama.2018.20588

Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis

2019

Conference Publication

Postpartum relapse after first on-study pregnancy in RRMS patients treated with alemtuzumab in the phase 2 and 3 clinical development program over 8 years

Celius, E. G., Achiron, A., Compston, D. A. S., Derwenskus, J., Devonshire, V., Hellwig, K., Hutton, G. J., McCombe, P., Moore, M., Oh, J., Simm, R. F., Sousa, L., Vincent, S. G., Chung, L., Daizadeh, N., Mitchell, C. and Rog, D. (2019). Postpartum relapse after first on-study pregnancy in RRMS patients treated with alemtuzumab in the phase 2 and 3 clinical development program over 8 years. 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm Sweden, 11-13 September 2019. London, United Kingdom: Sage Publications.

Postpartum relapse after first on-study pregnancy in RRMS patients treated with alemtuzumab in the phase 2 and 3 clinical development program over 8 years

2019

Conference Publication

Pregnancy Outcomes in Patients with MS Treated with Teriflunomide: Clinical Study and Postmarketing Data

McCombe, P., Vukusic, S., Coyle, P. K., Jurgensen, S., Truffinet, P., Benamor, M., Poole, E., Chavin, J. and Chambers, C. (2019). Pregnancy Outcomes in Patients with MS Treated with Teriflunomide: Clinical Study and Postmarketing Data. Congress of the Pan Asian Committee for Treatment and Research in Multiple Sclerosis (PACTRIMS), Sydney, NSW Australia, 2018. London, United Kingdom: Sage.

Pregnancy Outcomes in Patients with MS Treated with Teriflunomide: Clinical Study and Postmarketing Data

2019

Conference Publication

Cladribine: a multicentre long-term efficacy biomarker australian study (CLOBAS)

Lechner-Scott, Jeannette, Maltby, Vicky, Lyndon, Amanda, Monif, Mastura, Kilpatrick, Trevor, Butzkueven, Helmut, Taylor, Bruce, McCombe, Pamela, Hodgkinson, Suzanne, Fabis-Pedrini, Marzena, Kermode, Allan, Barnett, Michael and Kalincik, Tomas (2019). Cladribine: a multicentre long-term efficacy biomarker australian study (CLOBAS). Annual Scientific Meeting of the Australian and New Zealand Association of Neurologists (ANZAN), Sydney, Australia, May 21-24, 2019. London, United Kingdom: B M J Group. doi: 10.1136/jnnp-2019-anzan.119

Cladribine: a multicentre long-term efficacy biomarker australian study (CLOBAS)

2019

Conference Publication

Alemtuzumab maintains efficacy on clinical and MRI disease activity outcomes, including slowing of brain volume loss, over 9 years in RRMS patients: CARE-MS I follow-up (TOPAZ study)

Montalban, X., Arnold, D. L., Boyko, A. N., Comi, G., Hartung, H.-P., Havrdova, E. K., Inshasi, J. S., McCombe, P., Nakamura, K., Oreja-Guevara, C., Pelletier, D., Pozzilli, C., Scott, T. F., Vieira Alves Leon, S., Chung, L., Daizadeh, N., Afsar, S. and Selmaj, K. W. (2019). Alemtuzumab maintains efficacy on clinical and MRI disease activity outcomes, including slowing of brain volume loss, over 9 years in RRMS patients: CARE-MS I follow-up (TOPAZ study). 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm Sweden, 11-13 September 2019. London, United Kingdom: Sage Publications.

Alemtuzumab maintains efficacy on clinical and MRI disease activity outcomes, including slowing of brain volume loss, over 9 years in RRMS patients: CARE-MS I follow-up (TOPAZ study)

2019

Conference Publication

Alemtuzumab Improves Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in RRMS Patients Over 8 Years: CARE-MS I Follow-up (TOPAZ Study)

McCombe, P., Comi, G., Arnold, D. L., Boyko, A. N., Hartung, H-P., Havrdova, E. K., Inshasi, J. S., Nakamura, K., Oreja-Guevara, C., Pelletier, D., Pozzilli, C., Selmaj, K. W., Scott, T. F., Chung, L., Daizadeh, N., Afsar, S. and Van Wijmeersch, B. (2019). Alemtuzumab Improves Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in RRMS Patients Over 8 Years: CARE-MS I Follow-up (TOPAZ Study). Congress of the Pan Asian Committee for Treatment and Research in Multiple Sclerosis (PACTRIMS), Sydney, NSW Australia, 2018. London, United Kingdom: Sage.

Alemtuzumab Improves Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in RRMS Patients Over 8 Years: CARE-MS I Follow-up (TOPAZ Study)

2019

Journal Article

Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis

Kalincik, Tomas, Kubala Havrdova, Eva, Horakova, Dana, Izquierdo, Guillermo, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Grammond, Pierre, Onofrj, Marco, Lugaresi, Alessandra, Ozakbas, Serkan, Kappos, Ludwig, Kuhle, Jens, Terzi, Murat, Lechner-Scott, Jeannette, Boz, Cavit, Grand'Maison, Francois, Prevost, Julie, Sola, Patrizia, Ferraro, Diana, Granella, Franco, Trojano, Maria, Bergamaschi, Roberto, Pucci, Eugenio, Turkoglu, Recai, McCombe, Pamela A, Pesch, Vincent Van, Van Wijmeersch, Bart, Solaro, Claudio ... Butzkueven, Helmut (2019). Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 90 (4), 458-468. doi: 10.1136/jnnp-2018-319831

Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis

2018

Journal Article

The short and long-term effects of pregnancy on multiple sclerosis and experimental autoimmune encephalomyelitis

McCombe, Pamela A. (2018). The short and long-term effects of pregnancy on multiple sclerosis and experimental autoimmune encephalomyelitis. Journal of Clinical Medicine, 7 (12) 494, 494. doi: 10.3390/jcm7120494

The short and long-term effects of pregnancy on multiple sclerosis and experimental autoimmune encephalomyelitis

2018

Journal Article

Association of inflammation and disability accrual in patients with progressive-onset multiple sclerosis

Hughes, Jordana, Jokubaitis, Vilija, Lugaresi, Alessandra, Hupperts, Raymond, Izquierdo, Guillermo, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Grand'maison, Francois, Grammond, Pierre, Sola, Patrizia, Ferraro, DIana, Ramo-Tello, Cristina, Trojano, Maria, Slee, Mark, Shaygannejad, Vahid, Boz, Cavit, Lechner-Scott, Jeanette, Van Pesch, Vincent, Pucci, Eugenio, Solaro, Claudio, Verheul, Freek, Terzi, Murat, Granella, Franco, Spitaleri, Daniele, Alroughani, Raed, Jun, Jae-Kwan, Fambiatos, Adam, Van Der Walt, Anneke ... Hinson, Eloise (2018). Association of inflammation and disability accrual in patients with progressive-onset multiple sclerosis. JAMA Neurology, 75 (11), 1407-1415. doi: 10.1001/jamaneurol.2018.2109

Association of inflammation and disability accrual in patients with progressive-onset multiple sclerosis